RxDoctor Payments Data

David Ng

Interventional Pain Medicine · Temecula, CANPI 1942704135

Payments from drug & device makers

$1,949in general payments, 2019–2025

Across 50 payments — averaging $38.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$917
  • Medtronic$273
  • Curonix LLC$150
  • Si-bone, Inc.$137
  • Vertex$128
  • Collegium Pharmaceutical, Inc.$97
  • plus $246 from 8 others

What the payments were for

  • Travel & lodging$22912%
  • Food & beverage$1,72088%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific20$917
Medtronic7$273
Curonix LLC1$150
Si-bone, Inc.3$137
Vertex4$128
Collegium Pharmaceutical, Inc.5$97
AbbVie2$56
SPR Therapeutics, Inc2$52
Fidia Pharma USA Inc.1$32
Avanos Medical1$32
Vertos Medical, Inc.1$22
Tonix Medicines, Inc.1$19
Valinor Pharma, LLC1$17
Pfizer1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,949 in reported general payments places this provider in the 40th percentile of 188 interventional pain medicine providers in California.

See all interventional pain medicine providers in California

Medicare billing

Part B allowed, 2024
$202,496
Medicare patients
221
Services billed
1,950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl23$12,148
Xtampza ErOxycodone Myristate16$8,364
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen221$7,943
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen158$5,714
Lidocaine40$3,896
Oxycodone Hcl152$3,752
Naloxone Hcl44$2,846
Gabapentin152$2,570
Pregabalin65$2,544
Fentanyl18$2,517
Morphine Sulfate ErMorphine Sulfate57$2,061
Hydromorphone Hcl43$1,127
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine11$1,053
Cyclobenzaprine Hcl64$981
Tramadol Hcl57$924

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$97$8,36416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 188 interventional pain medicine providers in California.

Other interventional pain medicine in Temecula

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →